TABLE 6.

Impact of dose increase to 200 mg in partial responders at week 28

Response	Time (wk)	100 mg	200 mg	100/200 mg dose	Difference between100 mg and 100/200 mg
PASI75	12	57.1	60.1	56.4	−0.7
PASI75	28	73.5	79.8	72.9	−0.6
PASI75	52	77.8	84.4	79.6	1.8
PASI90	12	35.4	38.9	34.9	−0.5
PASI90	28	50.2	58.3	49.8	−0.4
PASI90	52	57.6	67.5	58.7	1.1
PASI100	12	9.0	11.5	8.8	−0.2
PASI100	28	12.3	17.8	12.2	−0.1
PASI100	52	16.0	23.5	15.7	−0.3

PASI, Psoriasis Area and Severity Index. Data are presented as % of subjects.

Expected percentage of subjects with PASI response, by regimen, with mean differences between the 100‐mg and 100‐/200‐mg regimens. The 100‐mg regimen means that all responders and partial responders received 100 mg over weeks 0–52, and week 28 nonresponders were discontinued and counted as nonresponders thereafter. The 200‐mg regimen has a similar description as the 100‐mg regimen, except with a different dose. The 100‐/200‐mg regimen means that all subjects started off with 100 mg, partial responders were switched to 200 mg at 28 weeks and nonresponders were discontinued and counted as nonresponders thereafter. No difference between 100 mg vs 100/200 mg is expected at weeks 12 and 28; however, results are presented for completeness. Times selected at 12, 28 and 52 weeks to reflect landmark time points in the phase 3 trials.